Using the industry peer median P/E Multiples multiple (trailing + forward), Abeona Therapeutics Inc. (ABEO) has a fair value of $12.16 based on 1 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| Abeona Therapeutics Inc.ABEO | 388 | 5.8x | — |
| Puma Biotechnology, Inc. | 351 | 11.3x | 27.6x |
| Industry Median | 11.3x | 27.6x | |
| (*) Profit after tax | 71 | ||
| Equity Value | 804 | ||
| (/) Outstanding shares | 66 | ||
| Fair Price | $12 | ||
Using the industry peer median EV/Revenue multiple (trailing + forward), Abeona Therapeutics Inc. (ABEO) has a fair value of $3.58 based on 7 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Abeona Therapeutics Inc.ABEO | 388 | 57.4x | 5.2x |
| Assembly Biosciences, Inc. | 464 | 5.6x | 6.5x |
| Puma Biotechnology, Inc. | 351 | 1.5x | 1.6x |
| Foghorn Therapeutics Inc. | 286 | 8.0x | 7.5x |
| Voyager Therapeutics, Inc. | 237 | 5.1x | 3.9x |
| Arcturus Therapeutics Holdings Inc. | 234 | 0.4x | 0.7x |
| Sagimet Biosciences Inc. | 165 | 44.7x | — |
| Humacyte, Inc. | 102 | 57.0x | 8.5x |
| Industry Median | 5.6x | 5.2x | |
| (*) Revenue | 6 | 64 | |
| = Enterprise Value | 33 | 333 | |
| (-) Net Debt | -53 | -53 | |
| Equity Value | 86 | 387 | |
| (/) Outstanding shares | 66 | 66 | |
| Fair Price | $1 | $6 | |
Using the PEG framework with analyst consensus forward EPS growth of 15.3%, the company has a fair value of $2.06 based on NTM EPS (FY2027) of $0.14. The current PEG ratio is 2.31.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
PEG is most informative for high-growth companies — the PEG sweet spot.
| EPS Growth RateForward | 15.3% |
| Adjusted Growth (clamped 8–25%) | 15.3% |
| Fair P/E | 15.3x |
| NTM EPS (FY2027) | $0.14 |
| Fair Value | $2.06 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $1.01 | — | — |
| FY2027E | $0.14 | -86.6% | 5 |
| FY2028E | $1.14 | +742.6% | 4 |
| FY2029E | $1.60 | +40.7% | 3 |
| FY2030E | $2.06 | +28.5% | 3 |
5Y Forward EPS CAGR: 15.3%
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $-84.9M | $-21.50 | — |
| FY2022 | $-39.7M | $-5.53 | — |
| FY2023 | $-54.2M | $-2.53 | — |
| FY2025 | $71.2M | $1.01 | — |
3Y Historical EPS CAGR: 0.0%
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.